Emcure Pharma Unveils Its ‘Largest’ R&D Centre in Gujarat.

Pune-based Emcure Pharmaceuticals Ltd. has inaugurated its largest Formulation Research and Development Centre in Ahmedabad, designed to facilitate breakthroughs in complex drug delivery systems.

"This will be our largest R&D facility. Out of the 550 scientists working with us across India, over 300 will be stationed at this new facility. We will focus heavily on complex molecules," said Satish Mehta, founder and CEO of Emcure Pharmaceuticals, during the inauguration on Thursday. The company did not disclose the investment made for the new R&D centre.

The new research centre will house around 350 skilled professionals dedicated to developing novel formulations, enhancing drug bioavailability, and creating patient-centric drug delivery solutions. Emcure operates five R&D facilities, with three focused on formulations research, one on Active Pharmaceutical Ingredients (API) research, and one on biopharmaceuticals research.

Mehta reflected on the company’s journey, saying, "I started in the mid-90s, and I wasn’t among the first 200 companies in India. But I realized that to make a mark, we needed differentiated products. In 2025, as I look back on 30 years, Emcure will have introduced the maximum number of differentiated new products."

Emcure Pharmaceuticals operates 13 manufacturing facilities across India. Its units in Jammu, Sikkim, and Bengaluru cater to the domestic market, while the Gujarat-based facilities focus on both domestic and international markets. Notably, the company operates an injectable manufacturing facility in Sanand (near Ahmedabad) that exports to Europe, the US, and emerging markets, along with tablet facilities in Kadu (Surendranagar) and Mehsana, both primarily export-driven.

When asked about the potential impact of a regime change in the US, which is a significant market for Emcure, Mehta reassured, "Since our listing on the stock exchange, our reliance on the US market is now less than two percent. We are focused on India, Europe, Canada, and emerging markets."

HBL